← Back to Search

Monoclonal Antibodies

Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine for Pancreatic Cancer (PanCAN-SR1 Trial)

Phase 1
Waitlist Available
Research Sponsored by Pancreatic Cancer Action Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up tumor response data from ct/mri scans will be taken at screening visit and every 8 weeks throughout study treatment, an average of 6 months;
Awards & highlights

PanCAN-SR1 Trial Summary

This trial is testing a new four-drug combination to see if it is safe and effective. The combination includes two different kinds of antibodies and two chemotherapy drugs.

Eligible Conditions
  • Pancreatic Cancer

PanCAN-SR1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~tumor response data from ct/mri scans will be taken at screening visit and every 8 weeks throughout study treatment, an average of 6 months;
This trial's timeline: 3 weeks for screening, Varies for treatment, and tumor response data from ct/mri scans will be taken at screening visit and every 8 weeks throughout study treatment, an average of 6 months; for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Confirm the recommended Phase 2/3 dose of canakinumab, spartalizumab, nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
Secondary outcome measures
Characterize the pharmacokinetics of canakinumab in patients with metastatic pancreatic cancer
Characterize the pharmacokinetics of gemcitabine in patients with metastatic pancreatic cancer
Characterize the pharmacokinetics of nab-paclitaxel in patients with metastatic pancreatic cancer
+8 more
Other outcome measures
Study the immune modulation effect of this 4-drug combination on the tumor micro-environment using CyTOF analysis from tissue biopsies.
Study the immune modulation effect of this 4-drug combination on the tumor micro-environment using flow cytometry from tissue biopsies.
Study the immune modulation effect of this 4-drug combination on the tumor micro-environment using immunostaining from tissue biopsies.
+8 more

PanCAN-SR1 Trial Design

1Treatment groups
Experimental Treatment
Group I: Canakinumab, spartalizumab, nab-paclitaxel and gemcitabineExperimental Treatment1 Intervention
Spartalizumab (PDR001),IV infusion, 400 mg, D1 of each 28-day cycle; Canakinumab (ACZ885), s.c. injection, 250 mg, Day 1 of each 28- day cycle; Gemcitabine, IV Infusion, 1000 mg/m2, Days 1, 8, 15 of each 28-day cycle; Nab-paclitaxel, IV Infusion, 125 mg/m2, Days 1, 8, 15 of each 28-day cycle.

Find a Location

Who is running the clinical trial?

Pancreatic Cancer Action NetworkLead Sponsor
5 Previous Clinical Trials
13,451 Total Patients Enrolled
Novartis PharmaceuticalsIndustry Sponsor
2,851 Previous Clinical Trials
4,197,580 Total Patients Enrolled
Amy Stoll-D'Astice, MSStudy DirectorPancreatic Cancer Action Network

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have the FDA granted approval to Canakinumab injection, spartalizumab, nab-paclitaxel and gemcitabine?

"Our in-house team at Power has assigned a safety score of 1 to canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine due to the limited data available from early phase clinical trials."

Answered by AI

What is the upper limit for participants in this medical trial?

"Sadly, this clinical trial is no longer accepting applicants. It was first posted on November 2nd 2020 and the last update to its listing occurred on April 5th 2022. However, if you are interested in other trials, 771 studies that involve adenocarcinoma are currently enrolling patients while 1149 research projects related to Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine have open positions available right now."

Answered by AI

Has Canakinumab injection, spartalizumab, nab-paclitaxel and gemcitabine been implemented in any prior research studies?

"Since 1997, canakinumab injection; spartalizumab, nab-paclitaxel and gemcitabine have been looked at in numerous clinical trials. City of Hope Comprehensive Cancer Center was the site of first examination. To date, there are 1931 completed studies with 1149 still active ones primarily situated in Boston, MA."

Answered by AI

To what illnesses are Canakinumab injection, spartalizumab, nab-paclitaxel, and gemcitabine typically employed as a remedy?

"Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine is the conventional treatment for active systemic juvenile idiopathic arthritis. This drug combination can also help treat other medical issues such as prior anthracycline exposure, metastatic neoplasms and locally advanced non-small cell lung cancer."

Answered by AI

Are there any vacancies for participants in this clinical experiment?

"Unfortunately, this clinical trial is not presently accepting participants; it was initially listed on November 2nd 2020 and last updated April 5th 2022. If you are still looking for other trials to take part in, 771 studies involving adenocarcinoma treatment are currently recruiting patients as well as 1,149 research projects that require the administration of Canakinumab injection with spartalizumab or nab-paclitaxel alongside gemcitabine."

Answered by AI
~2 spots leftby Mar 2025